Advances in HIV-1 Vaccine Volume II
Since the human immunodeficiency virus (HIV) was identified as the causative agent of acquired immunodeficiency syndrome (AIDS), the Human Immunodeficiency Virus (HIV) represents a worldwide threat to public health and the economy.It has been estimated that 35.3 (32.2-38.8) million people were living with HIV globally at the end of 2012. HIV has two major types, HIV-1 and HIV-2, which are further divided into groups, subtypes and recombinant forms. Globally, over 90% of HIV infections belong to HIV-1 group M viruses. Despite of the successful use of highly active antiretroviral therapy, the high genetic diversity of the HIV genomehas challenged the development of drugs and vaccines. Twenty-five years of research into development of a vaccine to prevent or control HIV-1 infection doesn’t lead to available protective vaccines. The aim of this book is to provide an overview of the status of research withinthe HIV vaccine.
Components of the Book:
  • FRONT MATTER
  • Chapter 13
    Stable 293 T and CHO Cell Lines Expressing Cleaved, Stable HIV-1 Envelope Glycoprotein Trimers for Structural and Vaccine Studies
  • Chapter 14
    Primary CD8+ T Cells from Elite Suppressors Effectively Eliminate Non-Productively HIV-1 Infected Resting and Activated CD4+ T Cells
  • Chapter 15
    Association between Hepatitis B Vaccine Antibody Response and CD4 Reconstitution after Initiation of Combination Antiretroviral Therapy in HIV-Infected Persons
  • Chapter 16
    AllostericInduction of the CD4-Bound Conformation of HIV-1 Gp120
  • Chapter 17
    Analysis of T Cell Responses to Chimpanzee Adenovirus Vectors Encoding HIV gag–pol–nefAntigen
  • Chapter 18
    A Human Immune Data Informed Vaccine Concept Elicits Strong and Broad T-Cell Specificities Associated with HIV-1 Control in Mice and Macaques
  • Chapter 19
    Quantification of the Epitope Diversity of HIV-1-Specific Binding Antibodies by Peptide Microarrays for Global HIV-1 Vaccine Development
  • Chapter 20
    The Effects of HIV Tat DNA on Regulating the Immune Response of HIV DNA Vaccine in Mice
  • Chapter 21
    HIV-1 Tat Immunization Restores Immune Homeostasis and Attacks the HAART-Resistant Blood HIV DNA: Results of a Randomized Phase II Exploratory Clinical Trial
  • Chapter 22
    Live-Virus Exposure of Vaccine-Protected Macaques Alters the Anti-HIV-1 Antibody Repertoire in the Absence of Viremia
  • Chapter 23
    Live Attenuated Rubella Vectors Expressing SIV and HIV Vaccine Antigens Replicate and Elicit Durable Immune Responses in Rhesus Macaques
  • Chapter 24
    Synthetic ImmunotherapyInduces HIV Virus Specific Th1 Cytotoxic Response and Death of an HIV-1 Infected Human Cell Line through Classic Complement Activation
Readership: Clinical practitioners and scientists in HIV vaccine and immunology; immunological researchers; medical, medicinal and immunological students and those with an interest in HIV vaccine.
Christian Brander
ICREA Senior Research Professor,IrsiCaixa Institute for AIDS Research, Spain.

Dan H Barouch
Professor of Medicine at Harvard Medical School and Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, United States.

George Dickson
University Chair of Molecular Cell Biology, Royal Holloway, University of London, Egham, Department of Biological Sciences, UK.

Lucy Dorrell
Associate Professor/Honorary Consultant Physician, Nuffield Department of Clinical Medicine, University of Oxford, UK.

Ronald E Bontrop
Research Director, Biomedical Primate Research Centre, Rijswijk, Netherlands.

and more...
Copyright © 2006-2021 Scientific Research Publishing Inc. All Rights Reserved.
Top